69065-87-8

Upstream product

• 89-61-2 2,5-dichloronitrobenzene 
• 89-63-4 4-Chloro-2-nitroaniline 
• 95-92-1 oxalic acid diethyl ester 
• 4755-77-5 Ethyl oxalyl chloride 

Downstream Products

• 6639-79-8 6-chloroquinoxaline-2,3(1H,4H)-dione 
• 855395-96-9 N-(2-amino-4-chloro-phenyl)-N'-(3-piperidino-propyl)-oxalamide 
• 6973-93-9 6-amino-1,2,3,4-tetrahydroquinoxaline-2,3-dione 
• 855396-09-7 N-(4-chloro-2-nitro-phenyl)-N'-(3-piperidino-propyl)-oxalamide 

Relevant academic research and scientific papers

Pyrrolylquinoxalinediones: A new class of AMPA receptor antagonists

Pyrrolylquinoxalinediones were synthesized and their affinities for the AMPA receptor were determined. Most compounds showed moderate to good affinities. The acetic acid derivative 8b exhibited a K(i) value of 70 nM and was equipotent to NBQX 1. Structure activity relationships are discussed. Selected compounds were tested for their potency to inhibit AMPA induced lethal convulsions in mice. In this in vivo model the compounds showed improved potency compared with NBQX.

2,3-quinoxalinediones for use as neuroleptics

Heterocyclic dihydroxyquinoxaline compounds having the formula STR1 wherein R 1 is hydroxy, alkoxy, aryloxy, aralkyloxy, cycloalkylalkoxy, cycloalkoxy, or acyloxy; andR 5, R 6, R 7 and R 8 independently are hydrogen, NO 2, halogen CN, SO 2 NR''R'', SO 2 R'', CF 3, or OR'', wherein R'' is hydrogen or C 1-4 -alkyl;The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use.The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.